A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market.
But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.
FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across multiple eye disease indications.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
New York, NY – November 19, 2025 – Wall Street is on high alert as the highly anticipated September 2025 jobs report, a critical barometer of the nation's economic health, is finally set to be released tomorrow, November 20, 2025. This crucial economic indicator has been delayed by a recent, record-long U.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning.
Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
The global financial markets are in the midst of a profound transformation, driven by an accelerating wave of technological advancements. From the intricate algorithms of Artificial Intelligence to the nascent power of quantum computing and the burgeoning might of renewable energy, these innovations are not merely incremental improvements; they are
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance, particularly by companies at the forefront of artificial intelligence (AI), tech stocks are now experiencing a noticeable downturn. This
Risk sentiment deteriorated sharply on Thursday despite federal agencies reopening after the longest government shutdown in U.S. history, as investors aggressively repriced Fed rate-cut expectations following a wave of hawkish remarks from central bank officials.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at immuno-oncology stocks, starting with Incyte (NASDAQ:INCY).
Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.
In the dynamic world of finance, where fortunes are made and lost in the blink of an eye, a chilling sentiment has begun to grip investors: the idea that stocks can, indeed, go down. This isn't merely a theoretical understanding; it's a palpable fear translating into cautious market behavior and
